Effect of Structured Yoga Practice on Glycemic and Hepatic Outcomes in Patients with Coexisting Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
Structured Yoga in T2DM with NAFLD
Keywords:
Yoga, Type 2 Diabetes Mellitus(T2DM), Non-Alcoholic Fatty Liver Disease (NAFLD),, HbA1c, Glycemic Control,Abstract
Background: Non-alcoholic fatty liver disease and type 2 diabetes mellitus often coexist and have similar metabolic risk factors. A key component of management is still changing one’s lifestyle. Hepatic and metabolic parameters may be improved by yoga, as an adjuvant therapy to the standard.
Aims and objective:
The current study aim was to evaluate the effect of yoga asanas on biochemical parameters of diabetes (FBS, PPBS, HbA1c) and NAFLD (ALT, AST).
Methodology:
This study was designed as a quasi-experiment and conducted at ESIC Medical College and Hospital, Faridabad. Total 160 participants with T2DM and NAFLD were recruited after obtaining the inform consent and ethics approval. The enrolled participant further divided in the two -group intervention and control group. Intervention group included the addition of the designed yogic program to the standard care of treatment and control group included the participant with standard care of treatment alone. The enrolled participants are followed up for 12 months. Biochemical parameter (Fasting Blood Sugar, Post-prandial Blood Sugar and HbA1c as glycemic and ALT and AST as Hepatic) is evaluated at month 3, month 6, month, month 9 and month 12.
Result:
The Intervention group showed significant reduction in FBS (153.18 ± 46.34 to 96.32 ± 21.21), PPBS (261.85 ± 56.23 to 162.10 ± 38.42 mg/dL) and HbA1c (8.19 ± 0.76% to 6.52 ± 0.66%) at 12 months (p < 0.0001), with significant inter-group differences for HbA1c at all follow-ups. ALT decreased from 62.58 ± 19.33 to 58.47 ± 15.37 U/L with significant inter-group differences at Months 9 and 12, while AST showed comparable changes between groups (p > 0.05). Overall, the intervention was associated with significant improvements in glycemic parameters and ALT levels over 12 months.
Conclusion:
Over 12 months, period of follow up, the intervention group showed good decrease in liver enzymes and significant long-lasting improvements in glycemic parameters (FBS, PPBG, and HbA1c). These results indicate that individuals with coexisting T2DM and NAFLD can benefit from an integrated approach that effectively improves both metabolic and hepatic outcomes.
Downloads
References
Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol (Lausanne). 2023;14:1149239.
Chen S, Deng S, Liu Y, Yin T. Effects of yoga on blood glucose and lipid profile of type 2 diabetes patients without complications: a systematic review and meta-analysis. Front Sports Act Living. 2022;4:900815.
Gowri MM, Rajendran J, Srinivasan AR, Bhavanani AB, Meena R. Impact of an integrated yoga therapy protocol on insulin resistance and glycemic control in patients with type 2 diabetes mellitus. Rambam Maimonides Med J. 2022;13(1):e0005.
Sharma S, Bhardwaj S, Gupta A, Katoch VM, Sharma KK, Gupta R. Influence of 24-week yoga intervention on cardiovascular risk factors and inflammatory markers in type 2 diabetes. Int J Yoga. 2023;16(1):27–33.
Kaur N, Majumdar V, Nagarathna R, Malik N, Anand A, Nagendra HR. Diabetic yoga protocol improves glycemic, anthropometric and lipid levels in high-risk individuals for diabetes: a randomized controlled trial from Northern India. Diabetol Metab Syndr. 2021;13:1–10.
Tabaeian SP, Rezapour A, Azari S, et al. Prevalence of non-alcoholic fatty liver disease in Iran: a systematic review and meta-analysis. J Clin Exp Hepatol. 2024;14(1):101209.
Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023;13:1087260.
Stine JG, Long MT, Corey KE, et al. Physical activity and nonalcoholic fatty liver disease: a roundtable statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2023;55(9):1717–.
Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 2019;1(6):468–79.
Huang M, Yang J, Wang Y, Wu J. Comparative efficacy of different exercise modalities on metabolic profiles and liver functions in non-alcoholic fatty liver disease: a network meta-analysis. Front Physiol. 2024;15:1428723.
Nath P, Panigrahi MK, Sahu MK, et al. Effect of exercise on NAFLD and its risk factors: comparison of moderate versus low-intensity exercise. J Clin Transl Hepatol. 2020;8(2):120.
Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes-associated NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2021;176:113888.
Cheng PN, Chen WJ, Hou CJ, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ. Taiwan Association for the Study of the Liver–Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases. Clin Mol Hepatol. 2024;30(1):16-36. doi:10.3350/cmh.2023.0315. PMID: 37793641; PMCID: PMC10776290.
Tyagi A, Cohen M. Yoga and heart rate variability: a comprehensive review of the literature. Int J Yoga. 2016;9(2):97–113.
Nugent NR, Brick L, Armey MF, Tyrka AR, Ridout KK, Uebelacker LA. Benefits of yoga on IL-6: findings from a randomized controlled trial of yoga for depression. Behav Med. 2021;47(1):21–30.
Park CL, Finkelstein-Fox L, Groessl EJ, Elwy AR, Lee SY. Exploring how different types of yoga change psychological resources and emotional well-being across a single session. Complement Ther Med. 2020;49:102354.
Hossein-Nezhad A, Yarjoo B, Niketeghad G, et al. Cyclic yoga for the prevention of age-related sarcopenia. Springer. 2016:S283–S283.
Momeni S, Mahdioun SS, Aghayari A. Cyclic yoga improves anthropometric indices, musculoskeletal disorders, and blood pressure in middle-aged women. J Bodyw Mov Ther. 2025;41:152–8.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837–53.
Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321(7258):405–12.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to overall hyperglycemia. Diabetes Care. 2003;26(3):881–5.
International Diabetes Federation. Guideline for management of postmeal glucose. Brussels: IDF; 2011.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non?alcoholic fatty liver disease: Practice guideline by AASLD. Hepatology. 2012;55(6):2005–23.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–50.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.
Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of NAFLD and its association with cardiovascular disease in type 2 diabetes. Diabetes Care. 2007;30(5):1212–8.
Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000.
Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of NAFLD. Dig Dis. 2010;28(1):155–61.
Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of NAFLD and diagnostic accuracy of non-invasive tests. Ann Med. 2011;43(8):617–49.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of NAFLD. Hepatology. 2016;64(1):73–84.
Published
How to Cite
License
Copyright (c) 2026 Nikku Yadav, Charu, Ashok Kumar Srivastav, A K Pandey
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
